These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17489582)

  • 1. Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity.
    Qin Z; Kastrati I; Chandrasena RE; Liu H; Yao P; Petukhov PA; Bolton JL; Thatcher GR
    J Med Chem; 2007 May; 50(11):2682-92. PubMed ID: 17489582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.
    Yu B; Dietz BM; Dunlap T; Kastrati I; Lantvit DD; Overk CR; Yao P; Qin Z; Bolton JL; Thatcher GR
    Mol Cancer Ther; 2007 Sep; 6(9):2418-28. PubMed ID: 17876041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator.
    Liu H; Bolton JL; Thatcher GR
    Chem Res Toxicol; 2006 Jun; 19(6):779-87. PubMed ID: 16780356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.
    Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR
    ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators.
    Qin Z; Kastrati I; Ashgodom RT; Lantvit DD; Overk CR; Choi Y; van Breemen RB; Bolton JL; Thatcher GR
    Drug Metab Dispos; 2009 Jan; 37(1):161-9. PubMed ID: 18936111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzothiophene and naphthalene derived constrained SERMs.
    Wallace OB; Bryant HU; Shetler PK; Adrian MD; Geiser AG
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5103-6. PubMed ID: 15380208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New scaffolds for the design of selective estrogen receptor modulators.
    Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
    O'Boyle NM; Barrett I; Greene LM; Carr M; Fayne D; Twamley B; Knox AJS; Keely NO; Zisterer DM; Meegan MJ
    J Med Chem; 2018 Jan; 61(2):514-534. PubMed ID: 28426931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selectively targeting estrogen receptors for cancer treatment.
    Shanle EK; Xu W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1265-76. PubMed ID: 20708050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor.
    Wang Z; Yang Y; Zheng X; Zhang T; Huang W; Yan D; Zhang W; Wang X; Shen Z
    J Pharm Pharmacol; 2018 Jul; 70(7):910-918. PubMed ID: 29582419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation.
    Liu H; Liu J; van Breemen RB; Thatcher GR; Bolton JL
    Chem Res Toxicol; 2005 Feb; 18(2):162-73. PubMed ID: 15720120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
    Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
    J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational approaches of drug design for the development of selective estrogen receptor modulators (SERMs), implicated in breast cancer.
    Makar S; Saha T; Swetha R; Gutti G; Kumar A; Singh SK
    Bioorg Chem; 2020 Jan; 94():103380. PubMed ID: 31757413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
    Mukherjee S; Saha A; Roy K
    Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
    Lv W; Liu J; Skaar TC; O'Neill E; Yu G; Flockhart DA; Cushman M
    J Med Chem; 2016 Jan; 59(1):157-70. PubMed ID: 26704594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridged androstenediol analogs as ER-beta selective SERMs.
    Blizzard TA; Gude C; Chan W; Birzin ET; Mojena M; Tudela C; Chen F; Knecht K; Su Q; Kraker B; Holmes MA; Rohrer SP; Hammond ML
    Bioorg Med Chem Lett; 2007 May; 17(10):2944-8. PubMed ID: 17448656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
    Hummel CW; Geiser AG; Bryant HU; Cohen IR; Dally RD; Fong KC; Frank SA; Hinklin R; Jones SA; Lewis G; McCann DJ; Rudmann DG; Shepherd TA; Tian H; Wallace OB; Wang M; Wang Y; Dodge JA
    J Med Chem; 2005 Nov; 48(22):6772-5. PubMed ID: 16250633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
    Bechmann N; Kniess T; Pietzsch J
    J Med Chem; 2019 Jul; 62(14):6525-6539. PubMed ID: 31099568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.